Results 1 to 3 of 3

Thread: BOSTON Life Sciences Files Investigational New Drug Application ...

  1. #1
    Senior Member Max's Avatar
    Join Date
    Jul 2001
    Location
    Montreal,Province of Quebec, CANADA
    Posts
    15,036

    BOSTON Life Sciences Files Investigational New Drug Application ...

    BOSTON Life Sciences Files Investigational New Drug Application ...
    Business Wire (press release) - San Francisco,CA,USA
    ... The results of these efficacy studies, as well as studies demonstrating
    compensatory axon growth in experimental spinal cord injury, have been
    published in ...

    Link Here

    [This message was edited by mk99 on 07-26-04 at 08:44 PM.]

  2. #2
    Thanks Max. This is excellent news for those with chronic injuries! Granted, we're probably looking at another 4-5 years by the time the stroke trials have been completed but planning a phase 1 clinical trial in the US with a drug for chronic injuries is unheard of here.

    Axosine does not work by limiting or reversing the brain damage caused by the interruption of arterial blood flow that results in stroke, but instead stimulates brain re-wiring after the stroke is complete.This means, among other things, that the so-called 'treatment window' is markedly extended with Axosine; though for how long we do not yet know. Our studies have shown that rats can begin Axosine treatment up to 24 hours after the completed stroke and still recover motor function. In contrast, thrombolytic and neuroprotective treatments must be given within a few hours of stroke onset (in rats or humans) for there to be any benefit. Clinically, neuroprotective and thrombolytic approaches have failed when given after the stroke is 'complete'; i.e., after there has been significant brain cell death and a functionally important region of the brain has been definitively destroyed by stroke. In contrast, Axosine promotes motor function recovery through the formation of new axonal branches and connections (rewiring) in the brain and spinal cord after the stroke is complete. We believe that Axosine has the potential to change the current clinical treatment paradigm for stroke and other Central Nervous System (CNS) injuries. If we are successful in treating stroke, we will then move on to the treatment of spinal cord injury and traumatic brain injury, two additional indications that could potentially benefit from Axosine treatment," added Dr. Lanser.

  3. #3
    Senior Member Max's Avatar
    Join Date
    Jul 2001
    Location
    Montreal,Province of Quebec, CANADA
    Posts
    15,036

    Welcome Sen


Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •